Skip to main content
SpringerLink
Log in

Beclometasone tops other ICS therapies

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Teva Respiratory.Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options. Media Release: 16 Sep 2009. Available from: URL: http://www.tevapharm.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beclometasone tops other ICS therapies. Pharmacoecon. Outcomes News 588, 8 (2009). https://doi.org/10.2165/00151234-200905880-00020

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905880-00020

Keywords

Search

Navigation